(2E)-Hexenoic Acid

(2E)-Hexenoic Acid

SCHEMBL451892

CCCC=CC(=O)O.CCCC=CC(=O)O.CCCC=CC(=O)O.CCCC=CC(=O)O.CCCC=CC(=O)O.CCCC=CC(=O)O.CCCC=CC(=O)O.CCCC=CC(=O)O.CCCC=CC(=O)O.CCCC=CC(=O)O.CCCC=CC(=O)O.CCCC=CC(=O)O.CCCC=CC(=O)O.CCCC=CC(=O)O.CCCC=CC(=O)O.CCCC=CC(=O)O.CCCC=CC(=O)O.CCCC=CC(=O)O.CCCC=CC(=O)O.CCCC=CC(=O)O.CCCC=CC(=O)O.CCCC=CC(=O)OCC

nearest known ligand 0.67

Full drug profile on Sugi Atlas →

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HCAR2 Q8TDS4 5/20 0.67
MAPT P10636 2/20 0.59
ALDH1A1 P00352 1/20 0.53
TTR P02766 1/20 0.44
DPP4 P27487 1/20 0.44
ATM Q13315 1/20 0.41
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA7 P43166 1/20 0.40
CA9 Q16790 1/20 0.40
CA14 Q9ULX7 1/20 0.40
NPSR1 Q6W5P4 1/20 0.39
CYP3A4 P08684 1/20 0.38
TAS1R3 Q7RTX0 1/20 0.38
TAS1R1 Q7RTX1 1/20 0.38
PTPN1 P18031 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
(2E)-Hexenoic Acid SCHEMBL28617152 1.00 HCAR2 (0.67) HCAR2MAPTALDH1A1TTRDPP4
Ethyl Fumarate SCHEMBL27194590 0.94 HCAR2 (0.77) HCAR2MAPTALDH1A1TTRDPP4
SCHEMBL755909 0.94 MAPT (0.66) HCAR2MAPTALDH1A1TTRDPP4
SCHEMBL29430520 0.94 MAPT (0.66) HCAR2MAPTALDH1A1TTRDPP4
SCHEMBL265418 0.94 MAPT (0.66) HCAR2MAPTALDH1A1TTRDPP4
Ethylene SCHEMBL27926804 0.90 MAPT (0.61) HCAR2MAPTALDH1A1TTRDPP4
SCHEMBL6322239 0.89 MAPT (0.66) HCAR2MAPTALDH1A1TTRDPP4
Trimethylammonium SCHEMBL27821912 0.88 MAPT (0.59) HCAR2MAPTALDH1A1TTRDPP4
SCHEMBL4582673 0.86 MAPT (0.68) HCAR2MAPTALDH1A1ATMCYP3A4
SCHEMBL4936379 0.86 MAPT (0.73) HCAR2MAPTALDH1A1TTRDPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 337 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240058293-A1 Nutritional Formulas Comprising Medium Chain Fatty Acids or Esters Thereof and Methods Related Thereto UNIV EMORY (US) 2024-02-22 US claimed
US-11826336-B2 Nutritional formulas comprising medium chain fatty acids or esters thereof and methods related thereto EMORY UNIVERSITY (US) 2023-11-28 US claimed
CN-116492339-A Composition, application thereof and pharmaceutical preparation 深圳君圣泰生物技术有限公司 2023-07-28 CN claimed
CN-111295203-B Methods and compositions for treating inflammatory bowel disease 深圳君圣泰生物技术有限公司 2022-09-06 CN claimed
US-20220142962-A1 METHODS OF TREATING HYPERCHOLESTEROLEMIA AMARIN PHARMACEUTICALS IRELAND LIMITED (IE) 2022-05-12 US claimed
US-11207286-B2 Self-emulsifying composition of w3 fatty acid MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2021-12-28 US claimed
US-20210283090-A1 Nutritional Formulas Comprising Medium Chain Fatty Acids or Esters Thereof and Methods Related Thereto UNIV EMORY (US) 2021-09-16 US claimed
US-11026913-B2 Nutritional formulas comprising medium chain fatty acids or esters thereof and methods related thereto EMORY UNIVERSITY (US) 2021-06-08 US claimed
US-11007173-B2 Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same AMARIN PHARMACEUTICALS IRELAND LIMITED (IE) 2021-05-18 US claimed
US-10888537-B2 Pharmaceutical compositions comprising omega-3 fatty acids AMARIN PHARMACEUTICALS IRELAND LIMITED (IE) 2021-01-12 US claimed
US-20130324607-A1 METHODS OF TREATING HYPERCHOLESTEROLEMIA AMARIN PHARMACEUTICALS IRELAND LIMITED (IE) 2013-12-05 US claimed
EP-2433630-A1 SELF-EMULSIFYING COMPOSITION OF 3 FATTY ACID Mochida Pharmaceutical Co., Ltd. (JP) 2012-03-28 EP claimed
US-20120065264-A1 SELF-EMULSIFYING COMPOSITION OF w3 FATTY ACID MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2012-03-15 US claimed
US-20100273878-A1 PREVENTIVE OR THERAPEUTIC DRUG FOR ALZHEIMER-TYPE DEMENTIA HASHIZUME KIYOSHI 2010-10-28 US claimed
US-20090286879-A1 Preventive or Therapeutic Drug for Alzheimer-Type Dementia MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2009-11-19 US claimed
US-20090209644-A1 LIPOTOXICITY RELIEVING AGENT AMARIN PHARMACEUTICALS IRELAND LIMITED (IE) 2009-08-20 US claimed
US-20080200707-A1 Lipotoxicity Relieving Agent MOCHIDA-PHARMACEUTICALS PHARMACEUTICAL CO., LTD. (JP) 2008-08-21 US claimed
EP-1955698-A1 PREVENTIVE/THERAPEUTIC AGENT FOR ALZHEIMER'S DEMENTIA MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2008-08-13 EP claimed
EP-1834639-A1 REMEDIAL AGENT FOR FAT TOXICITY MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2007-09-19 EP claimed
US-5120556-A Adding defatted corn germ IDEMITSU PETROCHEMICAL CO., LTD. (JP) 1992-06-09 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10888537-B2 Pharmaceutical compositions comprising omega-3 fatty acids ELOVL3, ELOVL6, ELOVL5 HCAR2 344/4885MAPT 3257/4885ALDH1A1 2432/4885
US-11007173-B2 Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same HMGCR, ELOVL3, SCD HCAR2 90/4885MAPT 3104/4885ALDH1A1 1417/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.